profit from every $100 of sales.
$0$100
Estrella Immunopharma
$0.09+25.07% today
-43.8% in 1 year
1-year low $0.051-year high $0.28
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Estrella Immunopharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Estrella Immunopharma | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Estrella Immunopharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- 0.11
- -4.6×
- 0.0×
- –
- –
- -50.9%
- -27.3%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- 126.0%
- -1,210.4%
- 185.8%
- -411.2%
- 126.0%
- –
Growth
- –
- –
- +76.6%
- –
- +58.4%
Financial health
- -0.1×
- 0.00
- 0.0%
- –
- 0.12
- 0.12
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 1%of 964
Bottom 19%of 898
Bottom 1%of 991
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 18, 2026 | -0.05 | -0.08 | +40.5% |
| Mar 18, 2026 | -0.14 | -0.18 | +22.2% |
| Nov 12, 2025 | -0.13 | -0.19 | +30.6% |
| Aug 12, 2025 | -0.15 | -0.07 | −119.0% |
| May 14, 2025 | -0.06 | -0.11 | +47.1% |
| Dec 31, 2024 | -0.03 | -0.12 | +75.8% |
| Nov 14, 2024 | -0.09 | – | – |
| Sep 26, 2024 | -0.11 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
28No pass
Benjamin Graham
32No pass
Philip Fisher
38No pass
Peter Lynch
62Pass
Joel Greenblatt
69Pass
Charlie Munger
50No pass
Terry Smith
43No pass
Questions about Estrella Immunopharma
Is Estrella Immunopharma a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Estrella Immunopharma AI analysis
What does Estrella Immunopharma do?
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. It is in Biotechnology.
Does Estrella Immunopharma pay a dividend?
No. Estrella Immunopharma does not pay a dividend at the moment.
Who are Estrella Immunopharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Estrella Immunopharma's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.